Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia

Journal of Medical Economics

Volumn 19, Issue 3, 2016, Pages 292-303

  Vekeman, Francis ^a   Sasane, Medha ^b   Cheng, Wendy Y ^c   Ramanakumar, Agnihotram V ^a   Fortier, Jonathan ^a   Qiu, Ying ^b   Duh, Mei Sheng ^c   Paley, Carole ^b   Adams Graves, Patricia ^d  

^a Groupe d'Analyse Ltee   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ANALYSIS GROUP   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adherence; Deferasirox; Deferoxamine; Healthcare costs; Healthcare resource utilization; Iron chelation therapy; Sickle cell disease; Thalassemia

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOMEGALY; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHELATION THERAPY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; FERRITIN BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; INFECTION; IRON CHELATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICATION COMPLIANCE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; THALASSEMIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; ADOLESCENT; ANEMIA, SICKLE CELL; COMORBIDITY; ECONOMICS; INSURANCE; LONGITUDINAL STUDY; UNITED STATES;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHELATION THERAPY; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; IRON CHELATING AGENTS; LONGITUDINAL STUDIES; MALE; MEDICAID; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; THALASSEMIA; TREATMENT OUTCOME; UNITED STATES;

EID: 84959131557     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1117979     Document Type: Article

References (34)

1. Kim J, Kim Y. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea. Value Health 2009; 12 (3 Suppl): S78-81
2. Payne KA, Rofail D, Baladi J-F, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther 2008; 25: 725-42
3. Vichinsky EP, Ohene-Frempong K, Thein SL, et al. Transfusion and chelation practices in sickle cell disease: a regional perspective. Pediatr Hematol Oncol 2011; 28: 124-33
4. Blinder MA, Vekeman F, Sasane M, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer 2013; 60: 828-35
5. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008; 83: 398-402
6. Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 2007; 3: 795-805
7. Trachtenberg FL, Gerstenberger E, Xu Y, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res 2014; 23: 2277-88
8. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154: 387-97
9. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-62
10. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-80
11. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-8
12. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-57
13. Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy 2006; 26: 1157-64
14. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239-52
15. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 2009; 52: 616-20
16. Jordan LB, Vekeman F, Sengupta A, et al. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. J Clin Pharm Ther 2012; 37: 173-81
17. Jensen GA, Li Y. Long-run health effects of cost-related non-adherence to prescribed medications among adults in late midlife. J Pharm Heal Serv Res 2012; 3: 85-93
18. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010; 362: 1553-5
19. Stefanacci RG, Guerin SP. Why medication adherence matters to patients, payers, providers. Managed care magazine online. Manag Care 2013; 22 (1); p. 37-39
20. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7
21. Bosi G, Crepaz R, Gamberini MR, et al. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart 2003; 89: 762-6
22. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93
23. Renfroe JL, Forbes P, Braunstein J, Neufeld EJ. Relationship of transfusion and iron-related complications to cost of care in thalassemia. ASH Annu Meet Abstr 2005; 106: 2240
24. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919-29
25. American Pharmacists Association. «Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality.» Journal of the American Pharmacists Association: JAPhA 54.3 (2013): 228-240.
26. Aitken, M., and S. Valkova. «Avoidable costs in US Healthcare.» IMS Institute for Healthcare Informatics, Parsippany, NJ (2013).
27. Blinder MA, Duh MS, Sasane M, et al. Age-related emergency department reliance in patients with sickle cell disease. J Emerg Med 2015; 49: 513-22.e1
28. Desrosiers M-P, Payne KA, Baladi J-F. Estimating the total cost of infused iron chelation therapy. ASH Annu Meet Abstr 2005; 106: 5576
29. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364: 146-56
30. Weissman L, Treadwell MVE. Evaluation of home desferal care in transfusion dependent children with thalassemia and sickle cell disease. J Pediatri Hematol Oncology 1996; 18 (4): 454-5
31. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol 2001; 56: 915-22
32. Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol 2002; 107: 150-7
33. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3
34. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood 2004; 104: 34-9